Xgenera

What Xgenera does

Xgenera is a UK-based, privately held biotechnology company developing miONCO, a blood-based multi-cancer early detection (MCED) test. The product uses a proprietary panel of microRNA (miRNA) biomarkers read from a single liquid biopsy blood draw, combined with machine learning algorithms that interpret the miRNA signal to predict the presence of cancer and localise its likely tissue of origin. Initial studies on a 21,000-patient cohort have reported sensitivity and specificity greater than 99% across all stages and detection coverage of up to 12 cancer types.

The company is pre-commercial. It is currently operating in the R&D and clinical-validation phase, including an ongoing large-scale retrospective trial with 8,000 patients announced in October 2024 and a transition of the assay from a microarray research format to a PCR-based format suitable for clinical-lab deployment. Its planned commercialisation path is to launch miONCO as a Laboratory Developed Test (LDT) in the United States by 2027, with the test ordered through clinical laboratories and healthcare providers serving at-risk adults and general-population screening customers. Pricing has not been disclosed.

Xgenera is funded by a combination of non-dilutive grants and venture capital. Cumulative funding disclosed is approximately £4.5 million, comprising a £2.4 million NIHR/UK Government grant, a £1 million collaborative partnership with molecular biology partner YouSEQ, and a £1.1 million seed round from QantX, Empirical Ventures, and Ascension VC, all announced in late 2024. The organisation remains small (1-10 employees) and is led by founder-CEO Dr. Andy Shapanis and founder-CSO Prof. Paul Skipp, with research ties to the University of Southampton.

Name

Xgenera

Legal name

Xgenera

Website

https://xgenera.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Xgenera is a UK-based, pre-commercial biotechnology company developing miONCO, a blood-based multi-cancer early detection test that uses proprietary microRNA biomarkers and machine learning to detect up to 12 cancer types, targeting healthcare providers and at-risk adults ahead of a planned 2027 US LDT launch.

Ownership category

akta.pro rank

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Laboratory Developed Test (LDT): Plans to commercialize miONCO as a laboratory developed test in the U.S. market by 2027. Revenue model will be laboratory testing services provided to healthcare providers and patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Xgenera is developing miONCO, a blood-based multi-cancer early detection (MCED) test that uses a proprietary panel of microRNA (miRNA) biomarkers combined with machine learning to detect up to 12 cancer types in a single test and predict the likely location of the cancer in the body. The company plans to commercialize the test as a laboratory developed test (LDT) in the United States by 2027 following an 8,000-patient retrospective trial.

Product overview

Xgenera is a focused single-product company developing miONCO, a transformative blood-based multi-cancer early detection (MCED) test. The product uses microRNA (miRNA) biomarkers combined with machine learning to simultaneously detect up to 12 cancer types from a single blood sample (liquid biopsy) and predict cancer location. The company recently completed its R&D phase and is conducting an 8,000-patient trial, with plans to launch commercially as a laboratory developed test by mid-2027.

Differentiator

Problem solved

Functional benefit

Brands

• miONCO: A transformative multi-cancer early detection (MCED) test that detects up to 12 different types of cancer through a single blood test using microRNA biomarkers and machine learning.
• miONCO-Dx

Products and services

• miONCO (miONCO-Dx) A blood-based multi-cancer early detection (MCED) test that uses a precisely selected panel of microRNA (miRNA) biomarkers combined with machine learning to detect up to 12 cancer types in a single test, while also predicting the likely location of the cancer in the body. Intended for healthcare providers and at-risk individuals seeking minimally invasive early cancer screening.

Quantifiable outcome

• 99% sensitivity and specificity across all cancer stages
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• YouSEQcoreStrategic or Co-development Partner · 10 September 2024Collaborative partnership worth £1 million for technology development and support. YouSEQ provides molecular biology expertise and technologies supporting Xgenera's diagnostic development.
• Against Breast CancerminorStrategic or Co-development PartnerCharitable organization supporting breast cancer research, providing research collaboration and support for Xgenera's cancer detection technology.
• University of SouthamptoncoreStrategic or Co-development PartnerAcademic research partner contributing scientific expertise and research capabilities. The company appears to have roots in Southampton-based research.

Scale indicators11 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• GRAIL: GRAIL developed Galleri, the leading blood-based multi-cancer early detection test, and is the closest direct competitor to Xgenera's miONCO. Both target the same MCED use case—single blood draw, multiple cancer types, tissue-of-origin prediction—and compete for the same health system, payer, and self-pay screening market.
• Natera: Natera is a major molecular diagnostics company with Signatera (tumor-informed MRD), EmpowerMCED and reproductive health assays. Its MCED initiative targets the same multi-cancer early detection market as miONCO with a blood-based approach.
• Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based cancer tests (Guardant360, Reveal, Shield) and has multi-cancer and minimal residual disease (MRD) programs. Xgenera's miRNA-based blood MCED overlaps directly with Guardant's broader liquid biopsy franchise in cancer detection.
• Freenome: Freenome is a privately held liquid biopsy company developing blood-based multi-cancer screening using cell-free DNA and methylomics. It is a direct competitor to miONCO in MCED, competing for the same health system and screening channel partnerships.
• Exact Sciences: Exact Sciences offers Cologuard and the Oncodetect/MCED program (originally Thrive Earlier Detection) and is a direct peer in blood-based cancer screening and early detection. Xgenera competes in the same MCED reimbursement, clinician adoption, and screening market that Exact Sciences is scaling.

Emerging players

• AnchorDx: AnchorDx is a Chinese-origin liquid biopsy company with multi-cancer early detection and lung cancer screening programs. While regionally focused, it represents an emerging peer in the global blood-based MCED category that Xgenera is targeting.
• Bluestar Genomics: Bluestar Genomics is an early-stage liquid biopsy company focused on epigenomic, cell-free DNA-based cancer detection. It is comparable as an emerging player pursuing the same MCED and oncology liquid biopsy market via a biomarker-plus-machine-learning approach.
• Singlera Genomics: Singlera Genomics is an early-stage liquid biopsy company developing multi-cancer early detection tests using cell-free DNA methylation approaches. It overlaps with Xgenera's MCED mission as an emerging competitor in blood-based cancer screening.

Broad incumbents

• Thermo Fisher Scientific (Life Sciences / Specialty Diagnostics): Thermo Fisher offers broad molecular diagnostics and life sciences tools, including qPCR instruments, reagents and clinical diagnostics services used in IVD and cancer testing. While not a direct MCED competitor, it is a broad incumbent supplying the technology stack (e.g., PCR) on which miONCO's commercial assay is built.
• Illumina: Illumina is the dominant NGS platform provider and parent/former parent of GRAIL. As a broad incumbent in genomics, Illumina enables and competes in the sequencing-based MCED space that Xgenera is working to enter with PCR-based miRNA testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/xgenera
• YouTubeyoutube.com/watch?v=2oA6VIWWrdI

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xgenera